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ess: surir@gosh.nhs.ukSummary Forced expiratory volume in 1 s (FEV1) is the usual primary outcome
variable in clinical trials in cystic ﬁbrosis (CF). Usually, several secondary outcomes
are also measured. We assessed which secondary outcomes are likely to give
additional clinically useful information about treatment effects, in order to inform
the design of future studies.
The study was performed as part of a trial comparing daily rhDNase with alternate
day rhDNase and hypertonic saline in CF. The primary outcome was FEV1. Secondary
outcomes were forced vital capacity (FVC), forced expiratory ﬂow at 25–75% of
forced vital capacity (FEF2575), number of pulmonary exacerbations, weight gain,
quality of life (QOL), and exercise tolerance. The usefulness of each secondary
outcome was investigated by assessing if the change in that outcome over the
treatment period could be predicted from the primary outcome.
Change in FEV1 correlated with changes in FVC (r2 ¼ 0:76, P ¼ 0:001), FEF25–75
(r2 ¼ 0:64, P ¼ 0:001), weight (r2 ¼ 0:08, P ¼ 0:001), and change in oxygen
saturation with exercise (r2 ¼ 0:08, P ¼ 0:001). However, it did not correlate with
changes in visual analogue score (VAS) with exercise, QOL, nor with the occurrence
of pulmonary exacerbations.
Only the outcomes QOL and VAS with exercise actually provided additional
information to FEV1 in this study.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
405 9200x5453; fax: +44 207 813 8514.
(R. Suri).
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In cystic ﬁbrosis (CF), most of the morbidity
and mortality is from pulmonary disease, which is
characterised by obstruction of the airways by
thick tenacious secretions that are difﬁcult to
clear.1 Treatment aimed at controlling airway
infection, reducing airway obstruction and improv-
ing nutritional status has been the cornerstone of
the successful management of CF. Recently, anti-
inﬂammatory therapy has been tested. Beyond
these basic strategies, symptomatic treatment
of the complications of the lung disease is also
essential.
When considering any new therapeutic interven-
tion, an additional beneﬁt over the current stan-
dard therapy or placebo needs to be demonstrated.
For individuals with CF, this beneﬁt ideally would be
increased survival time. However, as the estimated
median predicted life span of individuals with CF
approaches 40 years,2 survival time has become an
impractical measure of clinical efﬁcacy. Surrogate
markers of increased survival, such as improved
lung function, need to be assessed for the proposed
intervention.3
Most phase III clinical trials in CF4–6 have used
change in forced expiratory volume in 1 s (FEV1) as
the primary outcome, because it is easy to measure,
reproducible and has a relationship with mortality
in patients with CF.7–9 Several secondary outcomes,
which are based on the CF Foundation Consensus
Conference recommendations,3 are often measured
as well. Time to ﬁrst exacerbation has also become
a popular endpoint10 but there is no uniform
agreement as to what constitutes an exacerba-
tion11; many physicians now treat early without
waiting for formal criteria to be fulﬁlled; and many
patients will not exacerbate during the time period
of the trial, meaning that they will not contribute to
determination of efﬁcacy. Measuring many out-
comes may not merely prolong the trial visit unduly,
thus likely reducing patient co-operation, but also
lead to the possibility of false positive ﬁndings,
unless appropriate statistical corrections are made.
For example, by deﬁnition, one in 20 outcomes
would be expected to be outside the 95% conﬁdence
intervals, and might be considered ‘abnormal’.
Hence, only those secondary outcomes which give
information over and above that of the primary
outcome, and where observation of change on the
outcome is feasible within the trial follow up,
should be measured.
The aim of this report was to assess which
secondary outcomes gave clinically useful informa-
tion about treatment effects in a trial of rhDNase in
CF, additional to that obtained from the primaryoutcome (FEV1), in order to inform the design of
future treatment trials. A secondary outcome
measure was considered clinically useful if a
treatment comparison based on that measure could
not be predicted from the same comparison based
upon FEV1 measurements; that is, different conclu-
sions would be reached as to treatment efﬁcacy
based on FEV1 and the secondary outcome measure
under consideration.Methods
This study was conducted within a prospective
open, randomised cross-over trial comparing daily
rhDNase with alternate day rhDNase and hypertonic
saline (HS) in children with CF, that has been
reported in detail elsewhere.12 The study was
approved by the ethics committees of both institu-
tions. Each patient was allocated to receive, in
random order, consecutive 12 week treatments of
once-daily 2.5mg rhDNase, alternate day 2.5mg
rhDNase and twice-daily 5mls of 7% HS. There was a
2-week washout period between treatments.
The primary clinical outcome was change in FEV1.
Secondary outcomes that were measured at the
beginning and end of each treatment period were
forced vital capacity (FVC), forced expiratory ﬂow
between 25% and 75% of forced vital capacity
(FEF25–75), weight gain, exercise tolerance, quality
of life (QOL), and the number of pulmonary
exacerbations. Subjects were blinded to the results
of objective outcome measures (such as FEV1) when
completing subjective outcome measures (such as
the QOL questionnaire).
Lung function
At each visit, lung function was assessed by
standard spirometry using a compact spirometer
(Vitalograph, UK).13 FEV1, FVC and FEF25–75 were
measured in accordance with the American Thor-
acic Society guidelines.14
Exercise tolerance
The ‘‘3-min step test’’ was performed at each study
visit.15 The patients stepped up and down a single
15 cm step at 30 steps per minute for 3min
(regulated by a metronome). Oxygen saturation
(SaO2) was recorded continually during the exercise
test using a Biox 3700 pulse oximeter (Ohmeda,
USA). Change in SaO2 was calculated as the lowest
percentage oxygen saturation during exercise minus
the pre-exercise percentage oxygen saturation.
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recorded before and after the exercise.16 This
consisted of a 10 cm horizontal line with two anchor
points, one at each end. On the left (zero) it was
labelled, ‘‘not at all short of breath’’, while at the
other end (10 cm) it was labelled ‘‘the most
breathless I have ever felt’’. Patients put a mark
through the line where they thought their breath-
lessness ﬁtted on this scale, which was then
measured (in cm) from the zero point. Change was
calculated as post-exercise rating minus pre-exer-
cise rating, positive changes indicating an increase
in breathlessness.17
Quality of life
The Quality of Well-Being Scale self-administered
form 1  04 (QWB-SA UCSD Health Outcomes Assess-
ment Program) was used to assess QOL.18 The self-
administered form is a questionnaire that was ﬁlled
out by the patient and their carer together at each
study visit.
Pulmonary exacerbation
No universal deﬁnition exists for a pulmonary
exacerbation so a previously outlined protocol for
respiratory tract infections was used.19 A pulmonary
exacerbation was said to have occurred when a
patient was treated with parenteral antibiotics for
any four of the following 12 signs and symptoms:
change in sputum; new or increased haemoptysis;
increased cough; increased dyspnoea; malaise,
fatigue, or lethargy; temperature above 38 1C;
anorexia or weight loss; sinus pain or tenderness;
change in sinus discharge; change in physical
examination of the chest; decrease in pulmonary
function by 10% or more from a previously recorded
value; or radiographic changes indicative of pul-
monary infection.
Statistical analysis
The sample size for the trial was calculated on the
basis of change in FEV1 (primary clinical out-
come).12 The analysis focused on two separate pair
wise comparisons of the treatments: daily rhDNase
vs. HS, and daily vs. alternate day rhDNase, on the
basis of within-subject differences by analysis of
covariance. Between treatment comparisons of the
number of pulmonary exacerbations were made
using McNemar’s test of paired proportions. Adjust-
ment for additional covariates (treatment period,
quarterly season of the year and the child’s age at
the beginning of the period) was undertaken usingmultiple regression. A marginal model was used,
based on general estimating equations with robust
standard errors, which allows for the correlation
between observations taken on the same subject
over time.20
Comparison of outcomes
Using data from all treatment periods together,
Pearson’s correlation coefﬁcient was used to com-
pare percentage change in FEV1 with percentage
change in FVC and FEF25–75, and absolute change in
measures of exercise tolerance, weight, QOL, and
pulmonary exacerbations. Percentage change was
calculated as the difference between the post- and
pre-treatment measures, divided by the pre-treat-
ment measure. To accommodate within-patient
correlation between the two or three treatment
periods a patient contributed to, bootstrap techni-
ques were employed in the calculation of P-values
and 95% conﬁdence intervals for the correlation
coefﬁcient.21Results
Forty-eight children were randomised, eight to
each of the six possible treatment orders. Eight
children were unable to complete all three treat-
ment periods.12 Consequently 43 children were
included in the comparison of daily and alternate
day rhDNase, and 40 children in the comparison of
daily rhDNase and HS.
Effectiveness
Comparing mean FEV1 (primary outcome) between
the treatments, there was an 8% (95% CI: 2%–14%,
P ¼ 0:01) advantage for daily rhDNase over HS but
none for daily compared to alternate day rhDNase
(2%, 95% CI: 4% to 9%, P ¼ 0:55). There was no
evidence of treatment differences for any of the
secondary clinical outcomes.12 During the HS, daily
rhDNase, and alternate day rhDNase treatment
periods 15, 18, and 17 children experienced one
or more pulmonary exacerbations, respectively.
There was no evidence of a difference for either
treatment comparison (P ¼ 1:00 in each case).
Comparing the outcomes
Any potential association between the outcomes
measured was analysed to assess which secondary
outcomes gave information, additional to that
obtained from FEV1 about the effects of each
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in FEV1 correlated with changes in FVC (r2 ¼ 0:76,
P ¼ 0:001, 95% CI: 0.78–0.92) (Fig. 1), as expected,
and also with changes in FEF25–75 (r2 ¼ 0:64,
P ¼ 0:001, 95% CI: 0.73–0.85), weight (r2 ¼ 0:08,
P ¼ 0:001, 95% CI: 0.12–0.51) (Fig. 2) and change in
SaO2 with the 3min step test (r2 ¼ 0:08, P ¼ 0:001,
95% CI: 0.12–0.49). However, importantly it did not
correlate with changes in VAS with exercise
(r2 ¼ 0:01, P ¼ 0:144, 95% CI: 0.34 to 0.06), QWB
score (r2o0:01, P ¼ 0:411, 95% CI: 0.15 to 0.26),
nor with the occurrence of one or more pulmonary
exacerbations in the treatment period (r2o0:01,
P ¼ 0:76, 95% CI: 0.17 to 0.21).
Assessing the data for individual patients, change
in weight was only weakly associated with change in
FEV1 for individuals (Fig. 2). In some patients there
was an increase in weight after 12 weeks despite
there being a fall in FEV1. As expected, change inPe
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Figure 1 Positive correlation between percentage
change in FEV1 and percentage change in FVC
(r2 ¼ 0:76, P ¼ 0:001).
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Figure 2 Weak positive correlation between percentage
change in FEV1 and change in weight (r2 ¼ 0:08,
P ¼ 0:001).VAS with exercise and QWB score also did not match
change in FEV1 for all individuals.Discussion
The principle ﬁndings reported here are that only
the addition of measurement of QOL and VAS after
the step test added any useful information to
measurement of FEV1 in this medium-term trial.
Several secondary outcomes were measured in this
study to assess and compare the beneﬁts of the
three treatments. Due to the number of outcomes
measured, each study visit lasted about 1 h. The
main ﬁndings that daily rhDNase was more effective
than HS and that there was no evidence of
difference between daily and alternate rhDNase
were based on the primary outcome FEV1. However,
the important ﬁnding of this report was that only
measuring FEV1 may result in important beneﬁts
being missed, and changes in VAS with exercise and
QWB score gave additional, important information.
We also showed that FEV1 did not correlate with the
occurrence of a pulmonary exacerbation. However,
only a larger study than ours, with longer follow-up,
would be expected to show treatment differences
in this endpoint.
We cannot deﬁne from our data what is an
adequate r2 or P-value upon which to accept or
reject a clinically signiﬁcant difference between
endpoints, and in any case, such an attempt would
be somewhat artiﬁcial and arbitrary. For any
association with r2o1, there will be, by deﬁnition,
a less than perfect relationship between variables.
Furthermore, we acknowledge that the decision as
to whether a secondary outcome measure is useful
is more complex than just assessing whether it has a
high or low correlation with the primary endpoint.
Poor correlation with the primary endpoint could be
due to patient idiosyncracy or inability of the test to
discriminate between patients with CF. The point of
this report is, however, that in no patient would we
have altered our efﬁcacy conclusions by adding
another endpoint to the three we have highlighted,
namely FEV1, VAS and QWB. Thus, although as
expected there is no perfect agreement between
these endpoints and other secondary endpoints, the
differences would not result in a patient’s response
being wrongly categorised, and thus treatment
being given or withheld inappropriately. Nor do
the imperfections in the relationships alter the
conclusions of the trial, based on analyses of group
data.
For the study group, changes in FVC and FEF25–75
correlated with change in FEV1. The change in FVC
and FEF25–75 could be predicted from FEV1 and
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ever, measuring several spirometry parameters did
not prolong the study visit, as they are included in
the spirometry print-out and may be useful in
assessing patients with mild lung disease.
As expected from the low (if signiﬁcant) correla-
tion between change in FEV1 and change in weight,
FEV1 measures could not be used to predict changes
in weight in individual children. Although growth
failure and malnutrition are associated with pul-
monary morbidity in patients with CF,7,22,23 there
are disadvantages in measuring weight as an out-
come in short or medium-term trials. Confounding
variables such as dietary intake and the extent of
gastrointestinal dysfunction play a role in determin-
ing weight outcomes. During the study, one child
had a gastrostomy inserted and his weight increased
far in excess of any other weight gain recorded.
Weight changes may therefore be independent of
the trial medication. However, we acknowledge
that in other trials change in weight may be a useful
endpoint.
Change in VAS with exercise did not correlate
with FEV1. VAS is a subjective measure of breath-
lessness and is a measure of how breathless the
patients themselves feel. Previous studies have
shown it not to correlate with objective measures
of breathlessness, such as the 15 count score.24 A
problem with the VAS is that the anchor points
(‘‘not at all short of breath’’ or ‘‘the most breath-
less I have ever felt’’) are speciﬁc to the individual,
making comparisons between different people
harder to interpret, although it may be a valid
measure of change over time within the same
individual. The problems with the VAS highlight the
difﬁculties of measuring a subjective feeling or
symptom. However, it does not invalidate the use of
this score, as it is important to know how breathless
the patient feels, since this is the symptom causing
them concern. Objective measures of breathless-
ness or lung function will not take into account
the intensity of the ‘‘unpleasantness’’ of breath-
lessness, which is something only the patient
can know.
Change in SaO2 with exercise is an objective
measure of exercise response and tolerance, and
also breathlessness. The correlation between the
change in SaO2 with exercise and FEV1 suggests that
the 3-min step test is sensitive to a deterioration in
pulmonary function. Therefore for younger patients
unable to perform spirometry, performing the 3-min
step test over time may give the clinician a measure
of change in lung function. In older children who
can perform spirometry, any effect on exercise
tolerance due to the trial drugs, as assessed by
change in SaO2 during the 3-min step test, could bepredicted by changes in FEV1. However, we accept
that in other trials change in SaO2 may be a useful
endpoint. Furthermore, if patients are performing
the step test to measure changes in VAS, which has
been shown to be a useful outcome measure,
monitoring SaO2 as well will not take any extra
time.
Change in QOL, measured by the QWB scale, also
did not correlate with FEV1. At the time of our
study, no CF speciﬁc QOL measure was available,
therefore the QWB scale, which is a utility measure
of QOL, was used. Quittner and colleagues25 have
recently developed a disease-speciﬁc QOL measure
for children, adolescents and adults with CF.
Although the QWB scale has been validated for
patients with CF, it is not disease speciﬁc. Its main
advantage is its weighting of societal preferences
for various symptoms and functional states. How-
ever its main limitations are a lack of sensitivity to
clinically meaningful changes in CF and its uncertain
applicability to children and adolescents. Despite
this, it was interesting that QWB score did not
correlate with FEV1. Although FEV1 can be tracked
with time and various interventions,26 it does not
evaluate the impact of CF on the patient’s overall
health status and level of daily functioning. For
instance, it does not take into account other
pulmonary and non-pulmonary problems associated
with the disease or its treatment.
Measures of QOL provide information about the
impact of an illness and its treatment that may be
more meaningful to patients with CF and their
families than other conventional outcomes. They
assess beneﬁts and side effects of treatment and
can express outcome in terms of net beneﬁt since
they are not limited to one organ system. QOL
reﬂects an individual’s subjective evaluation of his
or her daily functioning and well-being because it
centres on the whole patient rather than just a
single measurement of physiological function. How-
ever, there is a risk that non-pulmonary events
unrelated to the trial drug, which can severely
affect a patient (e.g. diarrhoea) may inﬂuence the
QOL measure and lead to inaccurate conclusions of
how the trial drug is affecting the patient. This may
be less of a problem if a CF speciﬁc QOL measure is
used.
Pulmonary exacerbations cause progressive lung
damage in CF and affect QOL and are often assessed
as a secondary outcome. Furthermore, a compar-
ison of the occurrence of pulmonary exacerbations
is important to assess for unexpected adverse
effects of the drugs. At present there is no
standardised and universally accepted deﬁnition
for pulmonary exacerbation.3 The deﬁnition used in
this study was taken from the large rhDNase trial by
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shown that there is a lack of agreement in
diagnostic criteria to identify a pulmonary exacer-
bation among physicians caring for patients with CF.
This disagreement involves their approach to
diagnosis and management of a pulmonary exacer-
bation, and until this and other issues (above) are
resolved, using either pulmonary exacerbations or
time to ﬁrst exacerbation as an outcome is likely to
be difﬁcult.
In this study, for each trial drug the number of
treatment periods where an individual had one or
more pulmonary exacerbations were compared.
Although each treatment period was only 3 months,
this outcome gave an assessment about how well
the patient remained throughout the treatment
period and how this compared to the other
treatment periods. Although there was no increased
risk of pulmonary exacerbation during HS and
alternate day rhDNase, as compared with daily
rhDNase, the study duration may not have been long
enough (nor the patient numbers large enough) for
any signiﬁcant differences to become apparent.
Fuchs and colleagues19 have shown that daily
rhDNase statistically reduces the risk of pulmonary
infection compared to placebo, with patients on
once daily rhDNase spending a mean of 1.3 fewer
days in hospital for a pulmonary exacerbation,
compared to those on placebo. However even in
this 6 month, 968 patient study, these effects were
of little clinical signiﬁcance. There might be
differences in the exacerbation rate between the
treatments in this study, but these are not likely to
be very clinically important on the basis of the data
of Fuchs and colleagues.19
We have reported on the results from a single
trial, and therefore this paper must be considered
hypothesis generating, rather than deﬁnitive. Our
trial had a small sample size with short follow-up,
so outcomes based on events (e.g. pulmonary
exacerbations), which may only be affected by
treatment indirectly, may not be sensitive enough
to demonstrate a treatment effect. The examina-
tion of data on secondary endpoints from future
trials is needed to conﬁrm or refute whether our
results are generalisable.
In summary, in disagreement with the CF Con-
sensus Conference recommendations,3 only QOL
and VAS with exercise actually provided additional
information to FEV1 regarding the effectiveness of
the trial drugs in this study. The data raise the
possibility that redundant endpoints are being
recorded and reported, but this requires conﬁrma-
tion. Only large trials, which enrol several hundred
subjects for a prolonged period of time, will be able
to detect a change in the rate of pulmonaryexacerbation. In planning future trials in CF there
is a need to assess carefully which outcomes will
provide useful information and to ensure that the
study is sufﬁciently powered to detect differences
in all outcomes. This will then minimise the study
visit duration and inconvenience to participants.
Any additional outcomes measured need to be
justiﬁed, as performing several tests runs the risk
of ﬁnding false positive outcomes due to multiple
comparisons.Acknowledgements
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